Shots:
- InduPro has entered into a global strategic collaboration & licensing agreement with Eli Lilly to discover novel oncology treatments using InduPro’s proximity-guided platform
- Lilly will gain access to InduPro’s AI/ML-enabled MInt platform, with InduPro leading early discovery to identify co-target pairs & advance bispecific & multispecific antibody programs from the collaboration
- As per the deal, InduPro & Lilly will collaborate on up to three oncology targets, representing a total deal value of ~$950M, plus InduPro will receive an equity investment from Lilly
Ref: InduPro | Image: InduPro & Eli Lilly | Press Release
Related News: Eli Lilly to Acquire Ventyx for ~$1.2B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
